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Abstract
Background: While there is enough convincing evidence in childhood acute lymphoblastic
leukemia (ALL), the data on the pre-natal origin in childhood acute myeloid leukemia (AML) are
less comprehensive. Our study aimed to screen Guthrie cards (neonatal blood spots) of non-infant
childhood AML and ALL patients for the presence of their respective leukemic markers.
Methods: We analysed Guthrie cards of 12 ALL patients aged 2–6 years using immunoglobulin (Ig)
and T-cell receptor (TCR) gene rearrangements (n = 15) and/or intronic breakpoints of TEL/AML1
fusion gene (n = 3). In AML patients (n = 13, age 1–14 years) PML/RARalpha (n = 4), CBFbeta/
MYH11 (n = 3), AML1/ETO (n = 2), MLL/AF6 (n = 1), MLL/AF9 (n = 1) and MLL/AF10 (n = 1) fusion
genes and/or internal tandem duplication of FLT3 gene (FLT3/ITD) (n = 2) were used as clonotypic
markers. Assay sensitivity determined using serial dilutions of patient DNA into the DNA of a
healthy donor allowed us to detect the pre-leukemic clone in Guthrie card providing 1–3 positive
cells were present in the neonatal blood spot.
Results: In 3 patients with ALL (25%) we reproducibly detected their leukemic markers (Ig/TCR
n = 2; TEL/AML1 n = 1) in the Guthrie card. We did not find patient-specific molecular markers in
any patient with AML.
Conclusion: In the largest cohort examined so far we used identical approach for the backtracking
of non-infant childhood ALL and AML. Our data suggest that either the prenatal origin of AML is
less frequent or the load of pre-leukemic cells is significantly lower at birth in AML compared to
ALL cases.
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Acute lymphoblastic leukemia (ALL) is the most common
type of pediatric cancer while acute myeloid leukemia
(AML) occurs approximately 5 times less frequently in
children. There is evidence that some childhood acute
leukemias originate in utero. Indirect proof of the pre-
natal origin has been given by the cases of monozygotic
twins with genotype-identical leukemia [1]. Direct evi-
dence of the prenatal origin of ALL was demonstrated in
1997. Gale et al. backtracked MLL/AF4 fusion gene, a
leukemo-specific clonal marker, to neonatal dried blood
spots on filter-paper (Guthrie cards) of 3 children who
developed ALL at the ages of 5 months to 2 years [2].
Guthrie cards positive for the TEL/AML1 (ETV6/RUNX1)
were found in more than 10 ALL patients with this fusion
gene [3-6].
Clonal rearrangements of immunoglobulin (Ig) and T-
cell receptor (TCR) genes are found in >90% of childhood
ALL and can be used for retrospective analysis of cases
without detectable chromosomal translocations. Identical
rearrangements of Ig/TCR genes in twins and triplets with
concordant leukemia [7-9] and their presence in Guthrie
cards of patients who developed leukemia [10-12] pro-
vide satisfactory evidence of prenatal origin of ALL.
The availability of clonal markers in AML is lower.
Approximately 12 % of childhood AML cases bear the
translocation between chromosomes 8 and 21 resulting in
AML1/ETO (RUNX1/CBFA2T1) fusion gene. Transloca-
tion t(15;17) with PML/RARalpha fusion occurs in ~6%
and t(16;16) or inv(16) with chimera CBFbeta/MYH11 is
found with similar frequency among children with AML
[13]. Internal tandem duplications of FLT3 gene (FLT3/
ITD) are always in frame but vary in length. FLT3/ITD is
associated with poor prognosis and occurs in ~17% of
children with AML [14].
There are only few studies concerning in utero origin of
AML. Twins studies with AML patients indicate that both
infant [15,16] and non-infant [17] acute myeloid leuke-
mia can be initiated in utero. The AML1/ETO fusion gene
was detected in neonatal blood spots in 5/10 t(8;21) pos-
itive patients [18]. Apart from this study, only 3 single
cases of AML with positive Guthrie card were reported: for
PML/RARalpha, CBFbeta/MYH11 [19] and MLL/AF10
fusion genes [20], respectively.
Our study aimed to screen Guthrie cards in larger cohort
of non-infant childhood AML and ALL patients for the
presence of their respective leukemic markers. Clone-spe-
cific markers used for the screening included PML/RARal-
pha, AML1/ETO and CBFbeta/MYH11 fusion genes,
chimeric products with the MLL gene and for the first time
also the FLT3/ITD in patients with AML. In ALL cases we
used TEL/AML1 fusion gene and Ig/TCR gene rearrange-
ments. These molecular markers represent suitable targets
for backtracking of leukemic cells in newborn material,
because they are clonotypic and their incidence is ~40%
and >90% in AML and ALL, respectively. To our knowl-
edge, this is the largest study analyzing prenatal origin of
childhood leukemias presented so far.
Methods
Patients and controls
We studied the leukemic bone marrow cells at diagnosis
or relapse together with respective Guthrie cards of 13
pediatric patients with AML and 12 with ALL after obtain-
ing informed consent from the patients' parents. The
study was in compliance with the Helsinky Declaration
and was approved by the Ethical Committee of University
Hospital Prague – Motol and by the board of the Czech
Pediatric Hematology Working Group (CPH). All chil-
dren were diagnosed and treated in one of the CPH cent-
ers. Guthrie cards were obtained from the central
repositories in the Czech Republic. Guthrie cards from
age-matched healthy children were used as controls for
Guthrie cards analyses. Mononuclear cells from healthy
donors were used as negative controls for dilution experi-
ments.
Preparation of DNA
DNA from patients' and donors' cells was isolated by
QIAamp DNA Blood Mini Kit (Qiagen GmbH, Hilden,
Germany). Alternatively, an intact, high molecular weight
DNA necessary for amplification of large fragments was
isolated by the salting out protocol [21].
Determination of leukemia specific markers
Immunoglobulin and T cell receptor gene rearrangements
were identified as described previously [22,23]. Clonality
of the PCR products was determined by heteroduplex
analysis [24]. Monoclonal PCR products were cut from
the gel, reamplified with the same set of primers, purified
by QIAquick PCR Purification Kit (QIAGEN, Hilden, Ger-
many) and sequenced. FLT3/ITD were amplified by
genomic DNA PCR using primers 11F (5'-GCA ATT TAG
GTA TGA AAG CCA GC-3') and 12R (5'-CTT TCA GCA
TTT TGA GGG CAA CC -3') as described elsewhere [25].
PCR products were resolved on a 2% agarose gel stained
with ethidium bromide. Products bearing the duplication
were cut out, purified with Qiagen Gel Extraction Kit
(QIAGEN, Hilden, Germany) and sequenced. PML/RAR-
alpha and CBFbeta/MYH11 intronic (DNA) breakpoints
were found using multiplex long-distance polymerase
chain reaction (LD-PCR). We used 10 multiplex PCR reac-
tions for PML/RARalpha with 2 PML primers in intron 3
or 2 PML primers in intron 6 in combination with one of
the 5 RARalpha primers. For each CBFbeta/MYH11, six
individual PCR reactions were set up using 6 differentPage 2 of 7
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primer [19]. We amplified AML1/ETO fusion breakpoint
by 18 multiplex LD-PCR reactions. Nine ETO primers
were combined with two pairs of AML1 primers [18]. For
each TEL/AML1 patient, 30 individual PCR reactions were
set up for identification of genomic fusion sequence.
Primers TEL6B or TEL8B were used in combination with
one of the 15 AML1 primers [26].
AML1/ETO, TEL/AML1, PML/RARalpha and CBFbeta/
MYH11 LD-PCR reactions were performed using eLON-
GASE DNA polymerase (Invitrogen Life Technologies,
Carlsbad, CA) with high molecular DNA as a template. In
all LD-PCR reactions 1,7 mM MgSO4 was used and prod-
ucts were visualized on a 1,5 % agarose gel stained with
ethidium bromide. Positive bands were excised from gel
and purified by QIAEX II Gel Extraction Kit (QIAGEN
GmbH, Hilden, Germany).
All MLL fusions sequences were established at the DCAL
in Frankfurt. A long-distance inverse PCR method was
used to determine the genomic fusion breakpoints [27].
Sequencing was performed in the ABI PRISM® 310 Genetic
Analyzer with BigDye™ Primer v3.0 Sequencing Kit
(Applied Biosystems, Foster City, CA). Sequencing data
analyses were performed using Chromas version 1.5 soft-
ware (TECHNELYSIUM, Queensland, Australia). The
BLAST search was used to identify clonal Ig/TCR rear-
rangements, FLT3/ITD and genomic breakpoints of fusion
genes (NCBI, Bethesda, MD, USA).
Guthrie card PCR
DNA from Guthrie cards was isolated using QIAamp DNA
Blood Micro Kit (Qiagen GmbH, Hilden, Germany) or by
INSTAGENE™ DRY BLOOD kit (Bio-Rad, Hercules, CA,
USA). Alternatively, in some cases 1/8 of Guthrie card was
washed twice in 1 ml water (30 min each wash) to remove
PCR inhibitors [28], air-dried and used directly in PCR.
Presence and quality of DNA was assured by amplification
of the beta-globin housekeeping gene.
We designed primers for nested or semi-nested PCR to
amplify the patient-specific breakpoint (TEL/AML1,
AML1/ETO, PML/RARalpha, CBFbeta/MYH11 and MLL
rearrangements) or junctional region (Ig/TCR rearrange-
ments). Allele specific oligonucleotide (ASO) primers
were designed across the N specific segments (V-N-D, D-
N-J, V-N-J or V-N-Kde) of Ig/TCR rearrangements. In sam-
ples with FLT3/ITD the 5' end primers for first and second
round annealed to the junction between the wild-type
sequence and the ITD sequence. The 3' end primers
annealed to the wild type FLT3. Primers were designed
using the VECTOR NTI 8 Suite Software (INFORMAX,
Bethesda, MD, USA).
We established a PCR assay for each clonotypic sequence
prior to the analysis of the corresponding Guthrie card.
Assay specificity was determined using serial dilutions of
patients' diagnostic DNA sample into the DNA of a
healthy donor. Guthrie card PCRs were performed in a
separate room in a separate PCR box and only highly
diluted diagnostic samples (10-4-10-5) were used as posi-
Table 1: Results of Guthrie cards screening in patients with ALL
Patient Molecular marker Detection sensitivity % blasts at 
diagnosis
Age at diagnosis Guthrie card
ALL1 Vd2 10-4 N.A. 2 y 8 mo negative
VH3 10-5 negative
ALL2 VH3 10-4 50% 3 y 3 mo negative
TEL/AML1 10-4-10-5 negative
ALL3 VgI 10-5 >55% 4 y 5 mo positive
VkIA 10-4 negative
ALL4 Vd2 10-5 N.A. 3 y 6 mo positive
VH3 10-4 positive
ALL5 VH3 10-5 70% 4 y negative
ALL6 VH3 10-4 84% 1 y 8 mo negative
VH1 10-5 negative
ALL7 VH1 10-5 83% 3 y 3 mo negative
ALL8 VH3 10-4 79% 2 y 6 mo negative
ALL9 VH3 10-4 89% 2 y 3 mo negative
VH4 10-5 negative
ALL10 VgI 10-4 >30% 3 y 9 mo negative
ALL11 TEL/AML1 10-4-10-5 80% 5 y 7 mo negative
ALL12 TEL/AML1 10-5 77% 3 y 6 mo positivePage 3 of 7
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common anti-contamination procedures were followed
to avoid any potential risk of contamination.
All positive products from Guthrie card experiments were
sequenced to confirm the specificity of the product.
Results
Sensitivity of the experiments
Each PCR system for the Guthrie card analysis was opti-
mized using different annealing temperatures, different
MgCl2 concentrations and/or different primer concentra-
tions before we performed the Guthrie card PCR. Desired
sensitivity was > = 10-4 (i.e. 1 cell from diagnostic sample
among 10 000 other cells). We reached this sensitivity in
all systems and in all experiments except for 2 AML
patients (AML13 and AML8) who presented with a low
blast percentage (5.2 and 30%, respectively) at diagnosis.
In these patients, the sensitivity of some experiments (10
out of 24) was only 10-3.
The beta-globin control gene was amplified in all Guthrie
cards. Quantitative PCR analysis of beta-globin content in
5 randomly selected samples demonstrated that amount
of DNA extracted from 1 blood spot is 295 – 815 ng
(median 580 ng).
Targets, clonal-specific PCR and Guthrie card analysis
The characteristics of patients and results of the analyses
are summarized in Table 1 (ALL patients) and Table 2
(AML patients). In our group of 12 ALL patients we
detected 15 Ig/TCR rearrangements by heteroduplex anal-
ysis. In 3 patients we sequenced the TEL/AML1 genomic
breakpoint by LD-PCR. We designed ASO primers for Ig/
TCR rearrangements and specific primers amplifying the
TEL/AML1 intronic breakpoint region for patients with
the fusion gene. In one patient we screened the Guthrie
card for both Ig/TCR and TEL/AML1. In AML patients
FLT3/ITD and/or genomic breakpoints of different fusion
genes (PML/RARalpha, CBFbeta/MYH11, AML1/ETO,
MLL/AF6, MLL/AF9, and MLL/AF10) were used as clonal
markers. In one patient from our AML cohort the PML/
RARalpha fusion gene and also the FLT3/ITD were present
in diagnostic sample and tested in Guthrie card.
In three patients with ALL (= 25%) we reproducibly
detected identical clonotypic marker in the presentation
sample and in the neonatal blood spot on the Guthrie
card. The first patient harbored two independent rear-
rangements: TCR-delta Vd2/Dd3 and IgH VH3/JH5 and
both were detectable in Guthrie card. In the second
patient two PCR systems were optimized with identical
sensitivity: Ig-kappa Vk1/Kde and TCRgamma VgI/Jg1.3–
2.3. However, only the latter detected leukemic cells in the
Guthrie card. The third patient had the diagnostic TEL/
AML1 intronic fusion present in his Guthrie card. Overall,
we detected positive Guthrie card in 3/15 (= 20%) of Ig/
TCR markers in and 1/3 TEL/AML1 positive leukemias.
We did not find patient-specific molecular markers in any
Guthrie card of patients with AML.
Discussion
We examined neonatal blood spots for the presence of
clonotypic markers of (pre-)leukemic cells in the cohort of
25 patients with acute leukemia using a sensitive PCR
technique.
We confirmed the results of previous studies on prenatal
origin of ALL based on the same approach. In our cohort,
the presence of clonotypic marker of the leukemic cells
was backtracked in 3/12 ALL patients (25%). The data on
the prenatal origin of AML are less comprehensive. A con-
vincing study on AML backtracking in AML1/ETO patients
was published by Wiemels et al. [18] with 5/10 patients
Table 2: Results of Guthrie cards screening in patients with AML
Patient Molecular marker Detection sensitivity % blasts at 
diagnosis
Age at diagnosis Guthrie card
AML1 FLT3/ITD 10-5 87% 2 y 9 mo negative
AML2 FLT3/ITD 10-5 70% 8 y 9 mo negative
PML/RARalpha 10-4-10-5 negative
AML3 PML/RARalpha 10-4-10-5 >80% 13 y 9 mo negative
AML4 PML/RARalpha 10-4 55% 8 y 7 mo negative
AML5 PML/RARalpha 10-4-10-5 64% 7 y 4 mo negative
AML6 CBFbeta/MYH11 10-4-10-5 82% 5 y 8 mo negative
AML7 CBFbeta/MYH11 10-4 70% 6 y 3 mo negative
AML8 CBFbeta/MYH11 10-3-10-4 30% 2 y 6 mo negative
AML9 MLL/AF6 10-4-10-5 73% 1 y 5 mo negative
AML10 MLL/AF9 10-4-10-5 70% 1 y 7 mo negative
AML11 MLL/AF10 10-4 78% 5 y 4 mo negative
AML12 AML1/ETO 10-4-10-5 40% 9 y 4 mo negative
AML13 AML1/ETO 10-3-10-4 5,2% 14 y 8 mo negativePage 4 of 7
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were examined rarely. There are studies with single posi-
tive Guthrie cards for MLL/AF10, PML/RARalpha and
CBFbeta/MYH11 fusion genes, respectively [19,20], and
to our knowledge no other cases of non-infant childhood
AML were ever confirmed to be of pre-natal origin using
this approach. It is more demanding to perform a large
Guthrie card study on AML patients compared to ALL –
the diagnosis is about five times less frequent and there is
no universal marker for the genetic screening in AML cases
(unlike the Ig/TCR rearrangements in ALL). In our study
we were able to collect Guthrie cards from 13 AML chil-
dren with a suitable molecular marker – we found
intronic breakpoints in 12 patients with 6 different fusion
genes and, moreover, we used for the first time FLT3/ITD
for the analysis in two patients. Three different fusion
genes involving MLL locus were used in our study (MLL/
AF6, MLL/AF9 and MLL/AF10). MLL translocations are
closely linked to congenital and infant leukemias. How-
ever, to our knowledge only three non-infant patients
with MLL rearrangement detected in Guthrie card has
been presented so far. The case report of MLL/AF10 posi-
tive AML mentioned above [20] and two MLL/AF4 posi-
tive patients with ALL diagnosed at 2 and 6 years,
respectively [2,4]. In our study, the youngest AML patient
(case AML9 with MLL/AF6 fusion gene) was 18 months
old at diagnosis.
The limitation of the Guthrie card approach is the sensi-
tivity of the assay. A segment (usually 1/8) of a blood spot
analyzed in one PCR reaction contains only ~30 000
nucleated cells and the DNA on the spot can be of a poor
quality (depending on the storage conditions and time).
To estimate a yield of our DNA isolation from Guthrie
cards we performed beta-globin housekeeping gene quan-
titative PCR analysis in some samples. Providing the DNA
content of one cell is ~6 pg and there is approximately 200
000 – 300 000 nucleated cells in one spot our results show
that we were able to extract ~20–60% of the DNA theoret-
ically originally present on the Guthrie card. To our
knowledge this type of analysis has never been shown and
taking into account the storage time and conditions we
believe the result is very satisfactory.
We aimed to optimize the PCR to reach the sensitivity of
at least 10-4 in all patients and, moreover, we designed the
PCR so that the 1st round amplicon is shorter than 150–
200 base pairs enabling us to successfully analyze also
potentially highly fragmented DNA on the Guthrie card.
To determine the sensitivity of each target we used dilu-
tions of DNA from the diagnostic sample into DNA of
healthy volunteer in our dilution series. Although the
optimalization of such experiments is more laborious
compared to reactions using dilution into water (there is
higher possibility of non-specific amplifications from the
volunteer DNA) we believe this approach better reflects
the real situation, offers more reliable results and should
be used in all backtracking studies. We fulfilled the
assessed sensitivity criteria in all targets except for two
patients (AML8 and AML13) where only some of the rep-
licates of the 10-4 dilution were positive and the sensitivity
was determined as 10-3-10-4. However, both these two
patients had low blast count in the diagnostic sample
(that serves as a 100 dilution) and thus the reached sensi-
tivity in fact is 3 positive cells/10-4-10-5 cells and 5 positive
cells/10-5-10-6 cells in patients AML8 and AML13, respec-
tively. Therefore, our approach allowed us to detect the
pre-leukemic clone in all samples providing 1–3 positive
cells were present in the analyzed sample.
On one hand, the highest possible specificity of the anal-
ysis is crucial, however, on the other hand, the approach
used in the study requires an extreme caution in terms of
possible contamination. Once a clonal marker from the
diagnostic sample is amplified by PCR and used in
Guthrie card experiments as a positive control, threat of
contamination can not be excluded. Moreover, it is
impossible to distinguish a sporadic contamination from
real positivity. We applied very strict anti-contamination
precautions. The Guthrie card experiments were per-
formed in a separate room and only highly diluted diag-
nostic samples (10-4-10-5) were used as positive controls.
During the study we experienced no contamination in any
of the negative-control samples.
The results from the ALL cohort confirm that our
approach is appropriate both for the Ig/TCR targets (3/15
positive) and for the fusion gene analysis (1/3 positive).
Previously, Wiemels et al reported 5 out of 10 t(8;21)
childhood AML cases with fusion gene positive Guthrie
cards [18]. Only single examples of t(15;17), inv(16) and
MLL-AF10 with fusion gene positive Guthrie cards have
been reported [19,20]. As the present study included only
two cases of AML1-ETO positive leukemia, it is not possi-
ble to say that this occurs prenatally at a higher frequency.
Young age at diagnosis is probably not a crucial prerequi-
site for the pre-natal origin of childhood acute leukemia
as cases with a long latency to leukemia onset were
described [1,4,7,18,19,29]. However, the fact that the ALL
patients in our study were significantly younger at diagno-
sis compared to AML patients (median 3.5 and 6 years,
respectively) should be mentioned here.
The negative result in Guthrie card analysis can be caused
at least by three different reasons (providing the sensitiv-
ity of detection is adequate) – the leukemia does not orig-
inate prenatally, the pre-leukemic clone at birth is too
small to be present at Guthrie card spot or the marker usedPage 5 of 7
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leukemogenesis. The latter is probably the case with the
FLT3/ITD. This abnormality was never tested before as a
marker of leukemic cells in Guthrie cards. The positivity of
this abnormality in neonatal blood is rather unlikely as
the latest data indicate that this aberration has probably a
post-natal origin [30,31]. And indeed, we did not detect
the FLT3/ITD in any of the Guthrie cards tested.
The sensitive patient-specific PCR targeted either to the
FLT3/ITD breakpoint or to the intronic fusion of the vari-
ous chimeric genes provide potentially a very useful tool
not only for backtracking of leukemia but also for the
minimal residual disease monitoring in almost 50% of
children with AML, where common molecular marker is
unavailable (unlike Ig/TCR rearrangements in ALL).
In our study on childhood non-infant acute leukemias we
confirmed that the prenatal origin is common in ALL
patients (25% in our cohort) while all neonatal blood
spots in our AML cohort were negative. Although we
found all of the Guthrie cards from AML patients negative,
we do not think that our results completely contradict the
previous reports with positive neonatal blood spots of
AML patients [18-20]. However, we feel that with the
exception of AML1/ETO fusion gene, where the prenatal
origin has been proven reliably, reports of prenatal origin
in non-infant childhood AML are isolated single cases.
These should be confirmed by other studies or reports as
a false-positivity can not be ruled out completely with the
approach used. For example the E2A/PBX1 fusion gene
was found to be "weakly" positive in Guthrie cards of 2
out of 15 patients tested, and, nevertheless, the data on
E2A/PBX1 are interpreted as being suggestive of a post-
natal origin of this fusion gene [32].
Conclusion
The results of our study using the same approach for both
ALL and AML clearly indicate that either the prenatal ori-
gin of AML is less frequent or the load of pre-leukemic
cells is significantly lower at birth in AML compared to
ALL cases.
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